Rosetta Genomics Announces Launch of New Website

Rosetta Genomics Announces Launch of New Website 
Features Include Secure Physician Web Portal for Ordering Tests and
Receiving Results 
PHILADELPHIA, PA and REHOVOT, ISRAEL -- (Marketwired) -- 08/05/13 -- 
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces the
launch of a newly formatted website featuring an interactive, secure
physician web portal customized for ordering molecular diagnostic
testing services, enhanced and readily accessible information for
investors, improved navigation and an easier communication portal
with the Company. The new website can be accessed at
www.rosettagenomics.com.  
The physician web portal will connect Rosetta's CAP-accredited,
CLIA-certified laboratory seamlessly to physician offices, hospitals
and pathology laboratories in a secured electronic environment.  
In addition, the website includes a video entitled, "Cancer of
Unknown Primary (CUP), A Patient's Story," which chronicles a
patient's compelling journey commencing with a Cancer of Unknown
Primary diagnosis and the frustrations and difficulties associated
with not knowing his cancer's tissue of origin and then moving
forward with a determination of his cancer's origin through the use
of the Rosetta Cancer Origin Test(TM), and the patient's clinical and
emotional benefits associated with having this critical knowledge.
The complete story can be viewed at
http://www.rosettagenomics.com/a-patients-story. 
"The new website, with its sleek and modern feel, features enhanced
content, improved navigation, and an interactive physician portal.
Importantly, for patients and physicians the new website more clearly
communicates the connection between our corporate brand and the
information our tests provide. Our patient story brings to life the
real value underlying our work at Rosetta, which is to develop and
market innovative technologies that improve patients' lives," stated
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta
Genomics.  
"We are particularly excited about the innovative physician web
portal, which allows clinicians to order tests, review status reports
and receive patient test results directly from their office, or
remotely from mobile devices and tablets. Importantly, the ph
ysician
web portal will help physicians to provide their patients with
personalized treatment options at any time, and from any place. This
portal represents an innovative way of doing business which we
believe complements the model of modern medical practices and makes
for an easy and effective medium for us to service our physician
customers," added Mr. Berlin. 
About Rosetta Cancer Testing Services (formerly the miRview(R)
product line)
 Rosetta Cancer Tests are a series of microRNA-based
diagnostic testing services offered by Rosetta Genomics. The Rosetta
Cancer Origin Test(TM) can accurately identify the primary tumor type
in primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). Rosetta Mesothelioma Test(TM) diagnoses
mesothelioma, a cancer connected to asbestos exposure. The Rosetta
Lung Cancer Test(TM) accurately identifies the four main subtypes of
lung cancer using small amounts of tumor cells. The Rosetta Kidney
Cancer Test(TM) accurately classifies the four most common kidney
tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. Rosetta's assays are designed to
provide objective diagnostic data; it is the treating physician's
responsibility to diagnose and administer the appropriate treatment.
In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a
year may benefit from the Rosetta Cancer Origin Test(TM), 60,000 from
the Rosetta Mesothelioma Test(TM), 65,000 from the Rosetta Kidney
Cancer Test(TM) and 226,000 patients from the Rosetta Lung Cancer
Test(TM). The Company's assays are offered directly by Rosetta
Genomics in the U.S., and through distributors around the world. For
more information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215)
382-9000 or toll free (US) 1-888-522-7971. 
About Rosetta Genomics
 Rosetta develops and commercializes a full
range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. Rosetta's cancer testing services are commercially
available through its Philadelphia-based CAP-accredited,
CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with
the 2012 North American Next Generation Diagnostics Entrepreneurial
Company of the Year Award. 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test(TM), Rosetta's development or commercialization of molecular
diagnostics, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test(TM), Rosetta's
development of personalized medicine products and services constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta's Annual Report on Form 20-F for the year
ended December 31, 2012 as filed with the SEC. In addition, any
forward-looking statements represent Rosetta's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law. 
Company Contact: 
Rosetta Genomics 
Ken Berlin
President & CEO 
(609) 419-9000, ext. 1326 
investors@rosettagenomics.com 
Investor Contacts: 
LHA 
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com